NCCN Guidelines for Patients® | Esophageal Cancer - page 77

77
NCCN Guidelines for Patients
®
: Esophageal Cancer
Version 1.2013
Part 6: Adenocarcinomas
Par t 1
Par t 2
Par t 3
Par t 4
Par t 5
Par t 6
Par t 7
Par t 8
Par t 9
Second-line regimens
Preferred
Trastuzumab and cisplatin and fluoropyrimidine (5-FU or capecitabine)
Trastuzumab and other chemotherapy regimens that don’t include epirubicin
Docetaxel
Paclitaxel
Irinotecan
Other
Irinotecan and cisplatin
Irinotecan and fluoropyrimidine (5-FU or capecitabine)
Irinotecan and docetaxel
Alternative regimens
Gemcitabine, 5-FU, and leucovorin
Pegylated liposomal doxorubicin, cisplatin, and 5-FU
Mitomycin and irinotecan
Mitomycin, cisplatin, and 5-FU
Mitomycin and 5-FU
Etoposide
Erlotinib
Notes:
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
1...,67,68,69,70,71,72,73,74,75,76 78,79,80,81,82,83,84,85,86,87,...100
Powered by FlippingBook